Palladon (Hydromorphone Hydrochloride)

Hydromorphone hydrochloride, the active ingredient in Palladon, is an opioid analgesic presented as a strength/form for oral use. It is indicated for the management of moderate to severe pain in adult patients when alternative treatments are inadequate. GNH USA supplies Palladon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Palladon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydromorphone hydrochloride is an opioid that acts on the central nervous system to relieve pain. It is employed in several clinical situations: - Acute postoperative pain: provides rapid relief following surgical procedures. - Cancer‑related pain: helps control persistent pain associated with malignant disease. - Severe chronic non‑cancer pain: used when other analgesics are insufficient. - Palliative care: contributes to comfort in end‑of‑life settings.

Hydromorphone may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel motility. - Drowsiness: increased sleepiness or fatigue. - Dizziness: light‑headed feeling, especially when standing. - Dry mouth: reduced salivation. - Sweating: increased perspiration.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Severe hypotension: marked drop in blood pressure. - Bradycardia: unusually slow heart rate. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Confusion or delirium: altered mental status. - Dependence or withdrawal: signs of physical dependence with abrupt discontinuation.

When prescribing hydromorphone, clinicians should consider several safety measures: - Assess pain severity: confirm that opioid therapy is appropriate. - Evaluate respiratory function: monitor for signs of depression. - Review concomitant medications: avoid synergistic CNS depressants. - Screen for substance use disorder: assess risk of dependence. - Adjust dose in renal/hepatic impairment: use lower initial doses. - Store at ambient temperature: keep in original container, protect from moisture and light.

Hydromorphone can interact with a variety of medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Benzodiazepines: combined use can cause profound respiratory depression. - CNS depressants: alcohol, barbiturates, or other sedatives increase risk of sedation and respiratory compromise. - MAO inhibitors: may precipitate severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors: ketoconazole, erythromycin, and others may raise hydromor pall… - **